Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.